Trials / Conditions / Lung Neuroendocrine Neoplasm

Lung Neuroendocrine Neoplasm

9 registered clinical trials studyying Lung Neuroendocrine Neoplasm — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metast NCT06202066	Roswell Park Cancer Institute	Phase 2
Recruiting	Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tu NCT05918302	Grupo Espanol de Tumores Neuroendocrinos	Phase 3
Recruiting	Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendoc NCT04665739	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Neuroendocrine Tumors - Patient Reported Outcomes NCT05064150	University of Iowa	—
Recruiting	A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GE NCT04893785	National Cancer Institute, Naples	Phase 2
Active Not Recruiting	Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors NCT03600233	TaiRx, Inc.	Phase 2
Active Not Recruiting	Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurre NCT03110978	M.D. Anderson Cancer Center	Phase 2
Completed	Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors NCT02948946	H. Lee Moffitt Cancer Center and Research Institute	—
Completed	Safety and Efficacy of RAD001 in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor NCT01324492	Novartis Pharmaceuticals	Phase 1